These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 5081587)

  • 1. Quantitative structure-activity relationships of antineoplastic drugs: nitrosoureas and triazenoimidazoles.
    Hansch C; Smith N; Engle R; Wood H
    Cancer Chemother Rep; 1972 Aug; 56(4):443-56. PubMed ID: 5081587
    [No Abstract]   [Full Text] [Related]  

  • 2. Value of cytosine arabinoside (NSC-63878) plus 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388) therapy in advanced murine L1210 leukemia and enhancement of the combination with sequential doses of methotrexate (NSC-740) or 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU; NSC-409962).
    Kline I; Woodman RJ; Gang M; Cysyk RL; Venditti JM
    Cancer Chemother Rep; 1973; 57(3):291-8. PubMed ID: 4751255
    [No Abstract]   [Full Text] [Related]  

  • 3. Recent advances in the biochemical pharmacology of selected alkylating agents.
    Wheeler GP
    Transplant Proc; 1973 Sep; 5(3):1167-70. PubMed ID: 4738047
    [No Abstract]   [Full Text] [Related]  

  • 4. Therapy of malignant melanoma with an imidazole carboxamide and bis-chloroethyl nitrosourea.
    Costanza ME; Nathanson L; Lenhard R; Wolter J; Colsky J; Oberfield RA; Schilling A
    Cancer; 1972 Dec; 30(6):1457-61. PubMed ID: 4641757
    [No Abstract]   [Full Text] [Related]  

  • 5. Comparative studies on the chemical stability and therapeutic effectiveness of water-insoluble 5-(3,3-bis(2-chloroethyl)-1-triazeno)imidazole-4-carboxamide (NSC-82196) and its water-soluble hydrochloride against L1210 mouse leukemia.
    Woodman RJ; Kline I; Field RB; Gang M
    Cancer Chemother Rep; 1973; 57(4):383-91. PubMed ID: 4762437
    [No Abstract]   [Full Text] [Related]  

  • 6. Evaluation of antileukemic agents in advanced leukemia L1210 in mice. X.
    Kline I; Gang M; Tyrer DD; Venditti JM; Artis EW; Goldin A
    Cancer Chemother Rep 2; 1972 Nov; 3(1):1-69. PubMed ID: 4660732
    [No Abstract]   [Full Text] [Related]  

  • 7. Contributions of nitrosoureas to cancer treatment.
    Mitchell EP; Schein PS
    Cancer Treat Rep; 1986 Jan; 70(1):31-41. PubMed ID: 3002621
    [No Abstract]   [Full Text] [Related]  

  • 8. Relationship of structure to anticancer activity and toxicity of the nitrosoureas in animal systems.
    Johnston TP; Montgomery JA
    Cancer Treat Rep; 1986 Jan; 70(1):13-30. PubMed ID: 2935250
    [No Abstract]   [Full Text] [Related]  

  • 9. Combination therapy: some concepts and results.
    Skipper HE
    Cancer Chemother Rep 2; 1974 Mar; 4(1):137-45. PubMed ID: 4363649
    [No Abstract]   [Full Text] [Related]  

  • 10. Antitumor structure-activity relations. Nitrosoureas vs. L-1210 leukemia.
    Hansch C; Leo A; Schmidt C; Jow PY; Montgomery JA
    J Med Chem; 1980 Oct; 23(10):1095-101. PubMed ID: 7420354
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-activity relationships: nitrosoureas.
    Johnston TP
    Cancer Chemother Rep 3; 1972 May; 3(1):50-1. PubMed ID: 5065660
    [No Abstract]   [Full Text] [Related]  

  • 12. [Chemotherapy of malignant melanoma].
    Wagenknecht L
    Schweiz Med Wochenschr; 1973 Oct; 103(41):1426-8. PubMed ID: 4127413
    [No Abstract]   [Full Text] [Related]  

  • 13. Comparison of mutagenicity, antitumor activity, and chemical properties of selected nitrosoureas and nitrosoamides.
    Brundrett RB; Colvin M; White EH; McKee J; Hartman PE; Brown DL
    Cancer Res; 1979 Apr; 39(4):1328-33. PubMed ID: 421216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FIVB--a new combination of drugs in the treatment of cancer.
    Van Eden EB; Falkson G; Van der Merwe AM; Van Dyk JJ; Falkson HC
    S Afr Med J; 1973 Jun; 47(23):982-4. PubMed ID: 4714282
    [No Abstract]   [Full Text] [Related]  

  • 15. Chemotherapy of malignant melanoma.
    Luce JK
    Cancer; 1972 Dec; 30(6):1604-15. PubMed ID: 4565819
    [No Abstract]   [Full Text] [Related]  

  • 16. A structure--activity study of seven new water soluble nitrosoureas.
    Heal JM; Fox P; Schein PS
    Biochem Pharmacol; 1979 Apr; 28(8):1301-6. PubMed ID: 444298
    [No Abstract]   [Full Text] [Related]  

  • 17. Evaluation of 1-(2-chloroethyl-3-4-methylcyclohexyl)-1-nitrosourea (methyl-CCNU, NSC 95441) versus combined imidazole carboxamide (NSC 45338) and vincristine (NSC 67574) in palliation of disseminated malignant melanoma.
    Ahmann DL; Hahn RG; Bisel HF
    Cancer; 1974 Mar; 33(3):615-8. PubMed ID: 4131357
    [No Abstract]   [Full Text] [Related]  

  • 18. Antitumor 1-(X-aryl)-3,3-dialkyltriazenes. 2. On the role of correlation analysis in decision making in drug modification. Toxicity quantitative structure-activity relationships of 1-(X-phenyl)-3,3-dialkyltriazenes in mice.
    Hansch C; Hatheway GJ; Quinn FR; Greenberg N
    J Med Chem; 1978 Jun; 21(6):574-7. PubMed ID: 671454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemotherapeutic, carcinogenic, and cell-regulatory effects of triazenes.
    Schmid FA; Hutchison DJ
    Cancer Res; 1974 Jul; 34(7):1671-5. PubMed ID: 4833916
    [No Abstract]   [Full Text] [Related]  

  • 20. L1210 leukemia i.v. implanted as a model for testing short-chain nitrosourea analogs.
    Schmid JR; Fiebig HH; Eisenbrand G; Löhr GW
    J Cancer Res Clin Oncol; 1986; 111(1):31-4. PubMed ID: 3949848
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.